Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

BACKGROUND: Recent large-scale randomized studies have demonstrated that 2 new hormone preparations (abiraterone and enzalutamide) prolong survival in docetaxel-treated or -naïve castration-resistant prostate cancer patients. However, no studies have directly compared antitumor effects between these...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, Isao, Yamashita, Shimpei, Nishizawa, Satoshi, Kikkawa, Kazuro, Shimokawa, Toshio, Kohjimoto, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2018
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086929/
https://www.ncbi.nlm.nih.gov/pubmed/30054264
http://dx.doi.org/10.2196/11191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086929/
https://www.ncbi.nlm.nih.gov/pubmed/30054264
http://dx.doi.org/10.2196/11191

Ejemplares similares